We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
St. Jude (STJ) Launches PressureWire X After FDA Clearance
Read MoreHide Full Article
Global medical device company, St. Jude Medical, Inc. recently announced that it has launched the PressureWire X Guidewire fractional flow reserve (FFR) measurement system following the receipt of the U.S. clearance. This system is the latest in the PressureWire Guidewire series and is designed to offer better shapeability and shape retention for reducing vessel trauma. It also provides better accuracy and simplicity when treating patients during percutaneous coronary intervention (PCI), especially those with complex anatomies.
A PCI procedure, or coronary angioplasty, is a non-surgical procedure designed to open coronary blood flow blockages and restore blood flow to the hearts of patients living with coronary artery disease. PressureWire Guidewire FFR measurements are used by physicians to identify the severity of narrowings in the coronary arteries, which can result in more accurate diagnoses and better treatment decisions.
Headquartered in St. Paul, MN, St. Jude Medical has approximately 18,000 employees worldwide and focuses on five major areas that include heart failure, atrial fibrillation, neuron modulation, traditional cardiac rhythm management and cardiovascular.
St. Jude’s performance in the near term is likely to be dampened by the sluggish Cardiac Rhythm Management (CRM) market. The downside would stem from pricing pressures, austerity measures and health care reforms in the market. Moreover, lower demand for capital equipment owing to a tough hospital budget environment remains a major headwind for the company.
Boston Scientific has gained 25.7% year to date, much better than the S&P 500’s 4.3% over the same period. Over the past three months, the company’s earnings estimates for the current year have inched up 0.9% to $1.10 per share.
Cooper has seen eight estimates move higher for the current fiscal over the past 60 days, compared to no downward movement. Accordingly, earnings estimates for the year have moved up by 1.2% to $8.42 per share. The stock recorded a gain of 33.6% year to date.
NuVasive recorded an impressive 31.96% gain over the past one year compared to the S&P 500’s 5.8%. Over the next five years, the stock is expected to see 16.7% earnings growth compared to the industry average of 14.8%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
St. Jude (STJ) Launches PressureWire X After FDA Clearance
Global medical device company, St. Jude Medical, Inc. recently announced that it has launched the PressureWire X Guidewire fractional flow reserve (FFR) measurement system following the receipt of the U.S. clearance. This system is the latest in the PressureWire Guidewire series and is designed to offer better shapeability and shape retention for reducing vessel trauma. It also provides better accuracy and simplicity when treating patients during percutaneous coronary intervention (PCI), especially those with complex anatomies.
A PCI procedure, or coronary angioplasty, is a non-surgical procedure designed to open coronary blood flow blockages and restore blood flow to the hearts of patients living with coronary artery disease. PressureWire Guidewire FFR measurements are used by physicians to identify the severity of narrowings in the coronary arteries, which can result in more accurate diagnoses and better treatment decisions.
Headquartered in St. Paul, MN, St. Jude Medical has approximately 18,000 employees worldwide and focuses on five major areas that include heart failure, atrial fibrillation, neuron modulation, traditional cardiac rhythm management and cardiovascular.
St. Jude’s performance in the near term is likely to be dampened by the sluggish Cardiac Rhythm Management (CRM) market. The downside would stem from pricing pressures, austerity measures and health care reforms in the market. Moreover, lower demand for capital equipment owing to a tough hospital budget environment remains a major headwind for the company.
ST JUDE MEDICAL Price
ST JUDE MEDICAL Price | ST JUDE MEDICAL Quote
St. Jude currently has a Zacks Rank #4 (Sell).
Key Picks
Some better-ranked stocks in the broader medical sector are Boston Scientific Corporation (BSX - Free Report) , The Cooper Companies Inc. (COO - Free Report) and NuVasive, Inc. . All the three stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Boston Scientific has gained 25.7% year to date, much better than the S&P 500’s 4.3% over the same period. Over the past three months, the company’s earnings estimates for the current year have inched up 0.9% to $1.10 per share.
Cooper has seen eight estimates move higher for the current fiscal over the past 60 days, compared to no downward movement. Accordingly, earnings estimates for the year have moved up by 1.2% to $8.42 per share. The stock recorded a gain of 33.6% year to date.
NuVasive recorded an impressive 31.96% gain over the past one year compared to the S&P 500’s 5.8%. Over the next five years, the stock is expected to see 16.7% earnings growth compared to the industry average of 14.8%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>